{"entity":{"type":"insider","cik":"0001697316","url":"/insider/0001697316","json_url":"/insider/0001697316.json","name":"BIOS Fund I, LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":89,"n_filings":16,"first":"2022-09-07","last":"2025-06-30","span_basis":"filed_date"},"name_variants":[{"name":"BIOS Fund I, LP","source":"filing","n_filings":16,"first_seen":"2022-09-07","last_seen":"2025-06-30"}],"transactions":[{"id":4763975,"accession":"0001104659-25-063992","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-063992","line_url":"/filing/0001104659-25-063992#line-1","is_derivative":false,"issuer_cik":"0001652935","issuer_name":"ACTUATE THERAPEUTICS, INC.","issuer_ticker":"ACTU","issuer_name_source":null,"issuer_url":"/issuer/0001652935","owner_cik":null,"owner_name":"Cavu Management, LP; Bios Equity Partners II, LP; Kreis Leslie W.; BIOS Fund II NT, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; Cavu Advisors, LLC; Bios Equity Partners, LP; BIOS Fund II, LP; BIOS Fund I QP, LP","owner_display_name":"Cavu Management, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":71428.0,"shares_display":"71,428","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":499996.0,"total_display":"499,996.00","total_whole":"499,996","shares_owned_after":196428.0,"shares_owned_after_display":"196,428","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-06-30","scope":"insider"},{"id":4763894,"accession":"0001104659-25-059528","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-25-059528","line_url":"/filing/0001104659-25-059528","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Fund II, LP; BIOS Fund I QP, LP; BIOS Fund II QP, LP; BIOS Capital Management, LP; Bios Equity Partners, LP; BIOS Fund I, LP; BIOS Advisors GP, LLC; BIOS Fund II NT, LP; Bios Equity Partners II, LP; Fletcher Aaron G.L.","owner_display_name":"BIOS Fund II, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.09,"price_display":"3.09","price_state":"stated","total_value":123600.0,"total_display":"123,600.00","total_whole":"123,600","shares_owned_after":373178.0,"shares_owned_after_display":"373,178","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-13","scope":"insider","n_lines":5},{"id":4666547,"accession":"0001104659-25-059106","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001104659-25-059106","line_url":"/filing/0001104659-25-059106","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; Bios Equity Partners, LP; BIOS Capital Management, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP; BIOS Fund II NT, LP; BIOS Fund II, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60647.0,"shares_display":"60,647","price_per_share":3.38,"price_display":"3.38","price_state":"stated","total_value":204986.86,"total_display":"204,986.86","total_whole":"204,987","shares_owned_after":387396.0,"shares_owned_after_display":"387,396","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-12","filed_date":"2025-06-13","scope":"insider","n_lines":5},{"id":4666523,"accession":"0001104659-25-059106","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001104659-25-059106","line_url":"/filing/0001104659-25-059106","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; Bios Equity Partners, LP; BIOS Capital Management, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP; BIOS Fund II NT, LP; BIOS Fund II, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":950.0,"shares_display":"950","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":3230.0,"total_display":"3,230.00","total_whole":"3,230","shares_owned_after":408953.0,"shares_owned_after_display":"408,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-11","filed_date":"2025-06-13","scope":"insider","n_lines":5},{"id":4666495,"accession":"0001104659-25-059106","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-25-059106","line_url":"/filing/0001104659-25-059106","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; Bios Equity Partners, LP; BIOS Capital Management, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP; BIOS Fund II NT, LP; BIOS Fund II, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16.0,"shares_display":"16","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":54.4,"total_display":"54.40","total_whole":"54","shares_owned_after":409291.0,"shares_owned_after_display":"409,291","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-13","scope":"insider","n_lines":5},{"id":4327082,"accession":"0001104659-25-054422","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001104659-25-054422","line_url":"/filing/0001104659-25-054422","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; BIOS Fund II NT, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; BIOS Capital Management, LP; BIOS Fund II, LP; Bios Equity Partners, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20200.0,"shares_display":"20,200","price_per_share":3.03,"price_display":"3.03","price_state":"stated","total_value":61206.0,"total_display":"61,206.00","total_whole":"61,206","shares_owned_after":409296.0,"shares_owned_after_display":"409,296","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-29","filed_date":"2025-05-29","scope":"insider","n_lines":5},{"id":4327067,"accession":"0001104659-25-054422","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001104659-25-054422","line_url":"/filing/0001104659-25-054422","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; BIOS Fund II NT, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; BIOS Capital Management, LP; BIOS Fund II, LP; Bios Equity Partners, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":2.87,"price_display":"2.87","price_state":"stated","total_value":43050.0,"total_display":"43,050.00","total_whole":"43,050","shares_owned_after":416476.0,"shares_owned_after_display":"416,476","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-28","filed_date":"2025-05-29","scope":"insider","n_lines":5},{"id":4327049,"accession":"0001104659-25-054422","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-25-054422","line_url":"/filing/0001104659-25-054422","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Advisors GP, LLC; BIOS Fund I, LP; BIOS Fund II NT, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; BIOS Capital Management, LP; BIOS Fund II, LP; Bios Equity Partners, LP; Bios Equity Partners II, LP; BIOS Fund II QP, LP","owner_display_name":"BIOS Advisors GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21037.0,"shares_display":"21,037","price_per_share":3.05,"price_display":"3.05","price_state":"stated","total_value":64162.85,"total_display":"64,162.85","total_whole":"64,163","shares_owned_after":421808.0,"shares_owned_after_display":"421,808","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-27","filed_date":"2025-05-29","scope":"insider","n_lines":5},{"id":9223888,"accession":"0001104659-24-091370","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-24-091370","line_url":"/filing/0001104659-24-091370","is_derivative":false,"issuer_cik":"0001652935","issuer_name":"ACTUATE THERAPEUTICS, INC.","issuer_ticker":"ACTU","issuer_name_source":null,"issuer_url":"/issuer/0001652935","owner_cik":null,"owner_name":"BIOS Fund I QP, LP; BIOS Fund I, LP; BIOS Fund II NT, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; Bios Equity Partners II, LP; Bios Equity Partners, LP; Cavu Advisors, LLC; Cavu Management, LP; Kreis Leslie W.","owner_display_name":"BIOS Fund I QP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24999.0,"shares_display":"24,999","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":199992.0,"total_display":"199,992.00","total_whole":"199,992","shares_owned_after":131248.0,"shares_owned_after_display":"131,248","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-14","filed_date":"2024-08-20","scope":"insider","n_lines":3},{"id":2184534,"accession":"0001104659-24-089819","txn_seq":27,"anchor":"line-27","filing_url":"/filing/0001104659-24-089819","line_url":"/filing/0001104659-24-089819","is_derivative":false,"issuer_cik":"0001652935","issuer_name":"ACTUATE THERAPEUTICS, INC.","issuer_ticker":"ACTU","issuer_name_source":null,"issuer_url":"/issuer/0001652935","owner_cik":null,"owner_name":"BIOS Fund I, LP; BIOS Fund I QP, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Fund II NT, LP; Kreis Leslie W.; Cavu Advisors, LLC; Cavu Management, LP; Bios Equity Partners, LP; Bios Equity Partners II, LP","owner_display_name":"BIOS Fund I, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24999.0,"shares_display":"24,999","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":224991.0,"total_display":"224,991.00","total_whole":"224,991","shares_owned_after":980433.0,"shares_owned_after_display":"980,433","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-14","filed_date":"2024-08-14","scope":"insider","n_lines":3},{"id":2184517,"accession":"0001104659-24-089819","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0001104659-24-089819","line_url":"/filing/0001104659-24-089819","is_derivative":false,"issuer_cik":"0001652935","issuer_name":"ACTUATE THERAPEUTICS, INC.","issuer_ticker":"ACTU","issuer_name_source":null,"issuer_url":"/issuer/0001652935","owner_cik":null,"owner_name":"BIOS Fund I, LP; BIOS Fund I QP, LP; BIOS Fund II QP, LP; BIOS Fund II, LP; BIOS Fund II NT, LP; Kreis Leslie W.; Cavu Advisors, LLC; Cavu Management, LP; Bios Equity Partners, LP; Bios Equity Partners II, LP","owner_display_name":"BIOS Fund I, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":1259427.0,"shares_owned_after_display":"1,259,427","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-14","filed_date":"2024-08-14","scope":"insider","n_lines":2},{"id":2599841,"accession":"0001104659-24-065616","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-24-065616","line_url":"/filing/0001104659-24-065616","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Fund II NT, LP; Bios Equity Partners II, LP; BIOS Advisors GP, LLC; BIOS Capital Management, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; Bios Equity Partners, LP; BIOS Fund II, LP; BIOS Fund II QP, LP; BIOS Fund I, LP","owner_display_name":"BIOS Fund II NT, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.33,"price_display":"6.33","price_state":"stated","total_value":126600.0,"total_display":"126,600.00","total_whole":"126,600","shares_owned_after":429286.0,"shares_owned_after_display":"429,286","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-05-24","filed_date":"2024-05-28","scope":"insider","n_lines":3},{"id":2599821,"accession":"0001104659-24-065616","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-24-065616","line_url":"/filing/0001104659-24-065616","is_derivative":false,"issuer_cik":"0001697316","issuer_name":"Lantern Pharma Inc.","issuer_ticker":"LTRN","issuer_name_source":null,"issuer_url":"/issuer/0001697316","owner_cik":null,"owner_name":"BIOS Fund II NT, LP; Bios Equity Partners II, LP; BIOS Advisors GP, LLC; BIOS Capital Management, LP; Fletcher Aaron G.L.; BIOS Fund I QP, LP; Bios Equity Partners, LP; BIOS Fund II, LP; BIOS Fund II QP, LP; BIOS Fund I, LP","owner_display_name":"BIOS Fund II NT, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":6.25,"price_display":"6.25","price_state":"stated","total_value":62500.0,"total_display":"62,500.00","total_whole":"62,500","shares_owned_after":443174.0,"shares_owned_after_display":"443,174","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-05-23","filed_date":"2024-05-28","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":"2024-05-23|2599805","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001652935","name":"ACTUATE THERAPEUTICS, INC.","url":"/issuer/0001652935","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2024-08-14","last_seen":"2025-06-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001763950","name":"Lantern Pharma Inc.","url":"/issuer/0001763950","role":"Ten percent owner","n_filings":9,"first_seen":"2022-09-07","last_seen":"2025-06-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001701478","name":"Azitra Inc","url":"/issuer/0001701478","role":"Ten percent owner","n_filings":1,"first_seen":"2023-06-23","last_seen":"2023-06-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001455365","name":"COGNITION THERAPEUTICS INC","url":"/issuer/0001455365","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2022-11-16","last_seen":"2022-11-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001697316","retrieved_at":"2026-08-22T20:54:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}